CLAIMS

1. Use of a polypeptide that binds F-protein of hRSV with a K_D of $5x10^{-10}$ M or less, that neutralizes hRSV with an IC90 of 90 ng/mL or less, and that comprises, consists essentially of, or consists of three anti-hRSV immunoglobulin single variable domains, in the preparation of a medicament for use in the treatment of RSV infection in a young child,
wherein the anti-RSV immunoglobulin single variable domain comprises a CDR1 having the amino acid sequence of SEQ ID NO: 46, a CDR2 having the amino acid sequence of one of SEQ ID NOs: 49-50, and a CDR3 having the amino acid sequence of SEQ ID NO: 61, and
wherein the polypeptide is to be administered to the child suffering RSV infection by inhalation at a deposited dose of 0.020-0.040 mg/kg daily.

2. Use according to claim 1, wherein an inhaled dose is 0.20-0.40 mg/kg daily.

3. Use according to any one of claims 1 to 2, wherein a nominal dose is 1.00-2.00 mg/kg daily.

4. Use according to any one of claims 1 to 3, wherein the polypeptide is to be administered daily for 2 to 5 consecutive days preferably for 3 consecutive days.

5. Use according to any one of claims 1 to 4, wherein the young child is aged less than 24 months.

6. Use according to any one of claims 1 to 5, wherein the polypeptide is SEQ ID NO: 71.

7. Use according to any one of claims 1 to 6, wherein the polypeptide is to be administered as a monotherapy.

8. Use according to any one of claims 1 to 6, wherein at least one additional therapeutic agent is to be administered, preferably a bronchodilator.